CClinicalTrials.gg
Not yet recruitingNCT06959459Updated May 6, 2025

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities

An interventional study of Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC. and Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd. in Bone Defects of the Limbs, sponsored by Chinese PLA General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities: A Prospective, Randomized Controlled, Single-Blind, Non-Inferiority Clinical Trial

02

Conditions studied

  • Bone Defects of the Limbs
03

In context

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years old and ≤ 60 years old, regardless of sex;
  2. Cavitary bone defects in the limbs requiring bone grafting treatment;
  3. Bone defect volume ≥ 1 cm³ and ≤ 8 cm³, with only one bone defect requiring intervention;
  4. Subjects or their legal guardians can understand the study objectives, demonstrate sufficient compliance with the study protocol, and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Open fractures with wound contamination;
  2. Repair of infectious bone defects;
  3. Structural bone grafting required at the defect site;
  4. Osteofascial compartment syndrome in the affected limb scheduled for surgery;
  5. Presence of systemic infection, uncontrolled local infection at the surgical site, malignant tumor (including metastatic tumors) at the defect site, osteonecrosis at the defect site, severe nerve/soft tissue/vascular injury at the defect site, confirmed severe malnutrition, or dysfunction/failure of other vital organs;
  6. Calcium and phosphorus metabolic abnormalities (calcium/phosphorus levels > 1.5 times the upper limit of normal values);
  7. History of diabetes with fasting blood glucose ≥ 6.1 mmol/L;
  8. Coagulation dysfunction (prothrombin time [PT] or activated partial thromboplastin time [APTT] > 2 times the upper limit of normal values);
  9. Use of chemotherapeutic agents or receipt of radiotherapy within 3 months prior to enrollment;
  10. Cumulative use of corticosteroids or growth factors for ≥ 14 days within 1 month prior to enrollment;
  11. Long-term use of sedative-hypnotic drugs (continuous use for > 3 months) or non-steroidal anti-inflammatory drugs (NSAIDs, continuous use for > 3 months);
  12. Known allergy to bovine-derived materials or collagen products;
  13. Pregnant or lactating females;
  14. Participation in other interventional clinical trials for drugs or medical devices within 1 month prior to enrollment;
  15. Any other conditions where investigators, in their professional judgment, deem the subject ineligible to participate in the trial for the subject's safety or benefit.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

    Device: Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

  • Active comparator
    Control group

    Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

    Device: Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

Interventions

  • DeviceIntervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

    Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

  • DeviceControl group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

    Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

06

What researchers measure

Primary outcomes

  1. Bone graft fusion rate

    Time frame: 24weeks after surgery

Secondary outcomes

  1. Bone defect healing rate

    Time frame: 4 and 12 weeks after surgery

  2. New bone formation rate

    Time frame: 4, 12 and 24 weeks after surgery

  3. SF-36 scale

    Time frame: 24 weeks after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06959459
Lead sponsor
Chinese PLA General Hospital
Responsible party
Zhang Wei (Deputy head of orthopedics, Chinese PLA General Hospital) — Principal investigator
First posted
May 6, 2025
Start date
May 10, 2025 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 6, 2025

Study contacts

Wei Zhang
Contact
bszw@hotmail.com
+86 15334508850

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion